☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
metastatic triple-negative breast cancer
Roche's Tecentriq (atezolizumab) + Paclitaxel Fail to Meet the Primary Endpoint in P-III IMpassion131 Study for Patients with Meta...
August 7, 2020
Immunomedics' Trodelvy Receives the US FDA's Accelerated Approval for 2L Patients with Metastatic Triple-Negative Breast Cancer (T...
April 22, 2020
Merck & Co. Reports Results of Keytruda (pembrolizumab) + CT in P-III KEYNOTE-355 Study as 1L Treatment for Metastatic Triple-...
February 12, 2020
Immunomedics Reports the US FDA's Acceptance of BLA for Sacituzumab Govitecan to Treat Metastatic Triple-Negative Breast Cancer
December 27, 2019
Roche's Tecentriq (atezolizumab) + Abraxane Receive European Commission's Approval for Patients with PD-L1-Positive Metastatic Tri...
August 29, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.